REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 19th, 2024 • Rezolute, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledSeptember 19th, 2024 Company Industry JurisdictionThis Registration Rights Agreement (this “Agreement”) is made and entered into as of June __, 2024 between Rezolute, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
PREFUNDED COMMON STOCK PURCHASE WARRANT Rezolute, Inc.Security Agreement • March 14th, 2024 • Rezolute, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 14th, 2024 Company IndustryTHIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Rezolute, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REZOLUTE, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of _______, 20__ Debt SecuritiesIndenture • November 14th, 2023 • Rezolute, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 14th, 2023 Company Industry JurisdictionWhereas, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
11,250,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,750,000 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2024 • Rezolute, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 14th, 2024 Company Industry JurisdictionIntroductory. Rezolute, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 11,250,000 shares of its common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded warrants of the Company (in the form attached hereto as Exhibit C) to purchase 3,750,000 shares of Common Stock (the “Pre-Funded Warrants”). The 11,250,000 shares of Common Stock to be sold by the Company are called the “Firm Shares.” As used herein “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,250,000 shares of Common Stock. The additional 2,250,000 shares of Common Stock to be sold by the Company pursuant to such option are called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are c
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 26th, 2017 • Rezolute, Inc. • Pharmaceutical preparations • Illinois
Contract Type FiledDecember 26th, 2017 Company Industry JurisdictionREGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 22, 2017, by and between REZOLUTE, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 14th, 2023 • Rezolute, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 14th, 2023 Company Industry JurisdictionRezolute, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
PURCHASE AGREEMENTPurchase Agreement • August 4th, 2021 • Rezolute, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledAugust 4th, 2021 Company Industry JurisdictionTHIS PURCHASE AGREEMENT (the “Agreement”), dated as of August 2, 2021, is made by and between REZOLUTE, INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 4th, 2021 • Rezolute, Inc. • Pharmaceutical preparations • Illinois
Contract Type FiledAugust 4th, 2021 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 2, 2021, is entered into by and between REZOLUTE, INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
AMENDED AND RESTATED PREFUNDED COMMON STOCK PURCHASE WARRANT Rezolute, Inc.Prefunded Common Stock Purchase Warrant • May 15th, 2024 • Rezolute, Inc. • Pharmaceutical preparations
Contract Type FiledMay 15th, 2024 Company IndustryTHIS AMENDED AND RESTATED PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ______or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Rezolute, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REZOLUTE, INC. COMMON STOCK EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • December 18th, 2020 • Rezolute, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 18th, 2020 Company Industry JurisdictionRezolute, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc., as follows:
FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2016 • AntriaBio, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledNovember 4th, 2016 Company Industry JurisdictionTHIS FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of October 31, 2016 (the “Effective Date”) by and between AntriaBio, Inc. a Delaware corporation, having an address of 1450 Infinite Drive, Louisville, CO 80027 (“AntriaBio” or the “Company”), and Dr. Hoyoung Huh (“Executive”).
18,026,315 Shares of Common Stock And Pre-Funded Warrants to Purchase 12,921,055 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2022 • Rezolute, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 4th, 2022 Company Industry JurisdictionIntroductory. Rezolute, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 18,026,315 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), (ii) Class A warrants of the Company (in the form attached hereto as Exhibit C-1) to purchase 1,973,684 shares of Common Stock (the “Class A Pre-Funded Warrants”), and (iii) Class B warrants of the Company (in the form attached hereto as Exhibit C-2) to purchase 10,947,371 shares of Common Stock (the “Class B Pre-Funded Warrants” and, together with the Class A Pre-Funded Warrants, the “Pre-Funded Warrants”). The Shares and the Pre-Funded Warrants to be sold by the Company are collectively referred to as the “Securities.” Jefferies LLC (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Secur
AGREEMENT AND PLAN OF MERGERMerger Agreement • June 21st, 2021 • Rezolute, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJune 21st, 2021 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of June 18, 2021, is entered into between Rezolute, Inc., a Delaware corporation (the “Company”), and Rezolute Nevada Merger Company, a Nevada corporation and a wholly owned subsidiary of the Company (“NewCo”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec • Delaware
Contract Type FiledFebruary 6th, 2013 Company Industry JurisdictionTHIS AGREEMENT is made and entered into effective as of April 1, 2012 by and between AntriaBio, Inc., a Delaware corporation, having an address of 55 Broad St., 19th Fl, New York, NY (“AntriaBio” or the “Company”), and Mr. Steve R. Howe (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 19th, 2024 • Rezolute, Inc. • Pharmaceutical preparations • California
Contract Type FiledSeptember 19th, 2024 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 18, 2024 (the “Effective Date”) by and between Daron Evans, (“Employee”), and Rezolute, Inc. (the “Company”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 19th, 2024 • Rezolute, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledSeptember 19th, 2024 Company Industry JurisdictionTHIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made as of June 27, 2024, by and among Rezolute, Inc., a Nevada corporation (the “Company”), and each of those persons and entities, severally and not jointly, identified as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities together with their permitted successors and assigns, are referred to collectively as the “Purchasers” and each individually as a “Purchaser”. The Company and the Purchasers may each be referred to herein individually as a “Party” and collectively as the “Parties.”
SUBLEASE AGREEMENTSublease Agreement • September 22nd, 2017 • AntriaBio, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledSeptember 22nd, 2017 Company Industry JurisdictionTHIS SUBLEASE AGREEMENT (this “Agreement”) is made on March 17, 2017, by Elion, LLC (the “Sublandlord”) whose address is 1450 Infinite Drive, Louisville, Colorado 80027 and Antriabio, Inc. (the “Subtenant”) whose address is 1450 Infinite Drive, Louisville, Colorado 80027:
EMPLOYMENT AGREEMENTEmployment Agreement • August 6th, 2019 • Rezolute, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 6th, 2019 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of July 31, 2019 (the “Effective Date”) by and between Seline Miller, (“Employee”), and Rezolute, Inc. (the “Company”).
LICENSE AGREEMENTLicense Agreement • February 14th, 2018 • Rezolute, Inc. • Pharmaceutical preparations • California
Contract Type FiledFebruary 14th, 2018 Company Industry JurisdictionTHIS LICENSE AGREEMENT (this “Agreement”) dated as of December 6, 2017 (the “Effective Date”), is entered into between XOMA (US) LLC, a Delaware limited liability company, having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 (“XOMA”), and ANTRIABIO, INC., a Delaware corporation, having an address of 1450 Infinite Drive, Louisville, CO 80027 (“AntriaBio”). Each of XOMA and AntriaBio may be referred to herein as a “Party”, or jointly as the “Parties”.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • February 14th, 2018 • Rezolute, Inc. • Pharmaceutical preparations • California
Contract Type FiledFebruary 14th, 2018 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of December 6, 2017 (the “Effective Date”), by and among AntriaBio, Inc., a Delaware corporation (the “Company”), and XOMA Corporation, a Delaware corporation (“Purchaser”). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement (as defined below).
ANTRIABIO, INC.Subscription Agreement • January 5th, 2015 • AntriaBio, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 5th, 2015 Company Industry JurisdictionThe undersigned (the “Subscriber”) hereby irrevocably subscribes for and agrees to purchase from AntriaBio, Inc. (the “Company”) that number of Units (the “Units”) set out below at a price of $1.85 per Unit. Each Unit consists of one Common Share (as hereinafter defined) and one Warrant (as hereinafter defined). This offer of Units is part of an offering of up to 8,108,108 Units (the “Offering”). The Subscriber agrees to be bound by the terms and conditions set forth in the attached “Terms and Conditions of Subscription for Units” including without limitation the representations, warranties and covenants set forth in the applicable schedules attached thereto. The Subscriber further agrees, without limitation, that each of the Company and Paulson Investment Company, Inc. (the “Placement Agent”) may rely upon the Subscriber’s representations, warranties and covenants contained in such documents.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • April 19th, 2021 • Rezolute, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 19th, 2021 Company Industry JurisdictionTHIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of April 14, 2021 (the “Effective Date”) among SLR Investment Corp., fka Solar Capital Ltd., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (“SLR”), as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and the lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including SLR in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and Rezolute, Inc., a Delaware corporation with offices located at 201 Redwood Shores Parkway, Suite 315, Redwood City, CA 94065 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
SUBSCRIPTION AGREEMENT SHARES OF COMMON STOCK OF FITS MY STYLE INC.Subscription Agreement • June 14th, 2011 • Fits My Style Inc • New York
Contract Type FiledJune 14th, 2011 Company JurisdictionThe undersigned (the “Subscriber”) understands that Fits My Style Inc., a Nevada corporation (the “Company”), is offering for sale to the Subscriber the number of shares of the Company’s Common Stock, value per $0.001 (the “Common Stock”), set forth below the Subscriber’s name on the signature page hereto. The Subscriber acknowledges that it is not acting on the basis of any representations or warranties other than those set forth in this subscription agreement (this “Subscription Agreement”) and understands that the offering of the Common Stock (the “Offering”) is being made without registration of the Common Stock under the United States Securities Act of 1933, as amended (the “Act”), or any securities, “blue sky” or other similar laws of any foreign or domestic state (“State Securities Laws”), including without limitation, the jurisdiction in which the Subscriber resides.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 13th, 2020 • Rezolute, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 13th, 2020 Company Industry JurisdictionTHIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made as of October 8, 2020 by and among Rezolute, Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, identified as an Investor on the Schedule of Investors attached as Exhibit A hereto (the “Schedule of Investors”). Such persons and entities together with their permitted successors and assigns, are referred to collectively as the “Investors” and each individually as an “Investor”. The Company and the Investors may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2023 • Rezolute, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledMay 11th, 2023 Company Industry JurisdictionTHIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of January 8, 2023 (the “Effective Date”) by and between Rezolute, Inc., (formerly AntriaBio, Inc.), a Nevada corporation, having an address of 275 Shoreline Drive, Suite 500, Redwood City, CA 94065 (“Rezolute” or the “Company”), and Nevan Elam (“Executive”). This agreement amends and replaces the Amended and Restated Employment Agreement entered into on February 23, 2015 between the Company and the Executive (the “Original Agreement”) in its entirety.
ANTRIABIO DELAWARE, INC. STOCK OPTION CERTIFICATE Right to Purchase 3,500,000 Shares of Common Stock Exercise Price: $0.75 per ShareStock Option Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec • Delaware
Contract Type FiledFebruary 6th, 2013 Company Industry JurisdictionTHIS CERTIFIES THAT, for value received, Nevan Elam (the “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the Vesting Date (as defined below) and at or prior to the close of business on January 30, 2018 (the “Expiration Date”), but not thereafter, to subscribe for and purchase from AntriaBio Delaware, Inc., a Delaware corporation (the “Company”), up to 3,500,000 fully paid and nonassessable shares of the Company’s Common Stock, par value $0.01 per share (the “Common Stock”) at the Exercise Price (as defined herein). The Holder agrees that this certificate is for the Stock Option agreed to in the signed Employment Agreement between the Holder and the Company.
EXCHANGE AGREEMENTExchange Agreement • June 29th, 2016 • AntriaBio, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 29th, 2016 Company Industry JurisdictionThis EXCHANGE AGREEMENT (the “Agreement”) is made as of the ___ day of May 2016, by and between, AntriaBio, Inc., a Delaware corporation (the “Company”), and the investor signatory hereto (the “Investor”).
WEB SITE DESIGN CONSULTATION AGREEMENTWeb Site Design Consultation Agreement • June 14th, 2011 • Fits My Style Inc
Contract Type FiledJune 14th, 2011 CompanyNOW THEREFORE, in consideration of the covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree to the following:
LICENSE AGREEMENTLicense Agreement • October 13th, 2020 • Rezolute, Inc. • Pharmaceutical preparations
Contract Type FiledOctober 13th, 2020 Company IndustryThis LICENSE AGREEMENT (the "Agreement") is made as of September 15, 2020 (the "Effective Date") by and between Rezolute Inc., a Delaware corporation having its principal place of business at 201 Redwood Shores Parkway, Suite 315, Redwood City, California 94065, USA ("Rezolute"), and Handok Inc., a company registered under the laws of Republic of Korea, and having a registered office at 132 Teheran-ro, Gangnam-gu, Seoul 06235, Korea ("Handok"), on its own behalf and on behalf of its Affiliates. Rezolute and Handok may, from time to time, be individually referred to as a "Party" and collectively referred to as the "Parties".
SERVICES AGREEMENTServices Agreement • April 4th, 2014 • AntriaBio, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 4th, 2014 Company Industry JurisdictionTHIS AGREEMENT (this “Agreement”) is made as of March 28. 2014 (the “Effective Date”) by and between JSDC, Inc., a corporation organized under the laws of the State of Delaware with a place of business at 122 Red Maple Lane, Mountville, PA 17554 (“JSDC”) and AntriaBio, Inc., a Delaware corporation with a place of business at 890 Santa Cruz Avenue, Menlo Park, CA 94025 (“Company”).
3,263,157 Class C Pre-Funded Warrants to Purchase Shares of Common Stock Rezolute, Inc. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 4th, 2022 • Rezolute, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 4th, 2022 Company Industry JurisdictionIntroductory. Rezolute, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to certain purchasers (collectively, the “Purchasers”) Class C Pre-Funded Warrants (the “Warrants”) to purchase 3,263,157 shares of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company. The Warrants will be offered and sold to the Purchasers in a private placement (the “Placement”) without being registered under the Securities Act of 1933, as amended, and the rules and regulations of the Securities and Exchange Commission (the “Commission”) thereunder (collectively, the “Securities Act”), in reliance upon Section 4(2) (“Section 4(2)”) thereof and/or Regulation D (“Regulation D”) thereunder. Jefferies LLC (“Jefferies”) has agreed to act as lead placement agent and Cantor Fitzgerald & Co. (“Cantor”), Canaccord Genuity LLC (“Canaccord”), H.C. Wainwright & Co., LLC (“H.C. Wainwright”) and JMP Securities LLC (“JMP”) have agreed to act as co-placement agents (each, a “Place
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • March 6th, 2017 • AntriaBio, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 6th, 2017 Company Industry JurisdictionThe undersigned (the “Purchaser”) hereby irrevocably agrees to purchase from AntriaBio, Inc. (the “Company”) that number of shares of common stock (“Common Stock”), set out below at a price of $1.00 per Common Stock. The Purchaser agrees to be bound by the terms and conditions set forth in the attached “Terms and Conditions of Purchase for Common Stock” including without limitation the representations, warranties and covenants set forth in the applicable schedules attached thereto. The Purchaser further agrees, without limitation, that each of the Company and Samsung Securities Co., Ltd (the “Placement Agent”) may rely upon the Purchaser’s representations, warranties and covenants contained in such documents.
SUBSCRIPTION AGREEMENT SHARES OF COMMON STOCK OF FITS MY STYLE INC.Subscription Agreement • June 14th, 2011 • Fits My Style Inc • New York
Contract Type FiledJune 14th, 2011 Company JurisdictionThe undersigned (the “Subscriber”) understands that Fits My Style Inc., a Nevada corporation (the “Company”), is offering for sale to the Subscriber the number of shares of the Company’s Common Stock, value per $0.001 (the “Common Stock”), set forth below the Subscriber’s name on the signature page hereto. The Subscriber acknowledges that it is not acting on the basis of any representations or warranties other than those set forth in this subscription agreement (this “Subscription Agreement”) and understands that the offering of the Common Stock (the “Offering”) is being made without registration of the Common Stock under the United States Securities Act of 1933, as amended (the “Act”), or any securities, “blue sky” or other similar laws of any foreign or domestic state (“State Securities Laws”), including without limitation, the jurisdiction in which the Subscriber resides.
PROFORMA COMBINED FINANCIAL STATEMENTSShare Exchange and Reorganization Agreement • February 6th, 2013 • AntriaBio, Inc. • Services-business services, nec
Contract Type FiledFebruary 6th, 2013 Company IndustryOn January 30, 2013, AntriaBio, Inc. (the “Company”) entered into a share exchange and reorganization agreement (the “Share Exchange and Reorganization Agreement”) dated January 14, 2013, by and among the Company, AntriaBio Delaware, Inc., a Delaware corporation (“AntriaBio Delaware”), and the beneficial stockholders of AntriaBio Delaware (the “AntriaBio Stockholders”), pursuant to which the AntriBio Stockholders agreed to exchange all of the outstanding capital stock AntriaBio Delaware (the “AntriaBio Capital Stock”) for an aggregate of 35,284,000 shares of the Company’s common stock representing approximately 88% of the Company’s issued and outstanding capital stock giving effect to such issuance and the other transactions described herein. As a result of such transaction, AntriaBio Delaware shall become a wholly-owned subsidiary of the Company. In connection with the Share Exchange and Reorganization Agreement, Tungsten 74, LLC, the majority stockholder of the Company agreed to deli
AMENDMENT NO. 1 TO THE COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • May 15th, 2018 • Rezolute, Inc. • Pharmaceutical preparations
Contract Type FiledMay 15th, 2018 Company IndustryTHIS AMENDMENT NO. 1 (the “Amendment”) TO THE COMMON STOCK PURCHASE AGREEMENT dated December 6, 2017 (the “Agreement”) is entered into as of March 30, 2018, by and among Rezolute, Inc., a Delaware corporation (formerly known as AntriaBio, Inc.) (the “Company”), and XOMA Corporation, a Delaware corporation (“Purchaser”). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement.